Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
40 pending office actions • 20 art units • 39 examiners • 0 of 40 (0%) have an AI response strategy ready • 32 patents granted in the last 365 days
Yeda Research and Development Co. Ltd. maintains 38 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are spread across 37 distinct examiners and 20 distinct art units. The involvement of 20 distinct art units indicates that the company's research and development efforts span multiple specialized fields within the broader Biotechnology & Pharmaceuticals sector.
FERNANDO NMN IVICH is the busiest examiner for the portfolio, currently managing 2 pending office actions. This concentration of 2 is low relative to the 38 total pending actions, as the majority of the workload is distributed among 37 distinct examiners. This count of distinct examiners suggests that the company's patent strategy involves interactions with a variety of personnel at the patent office. The portfolio represents an active investment in the Biotechnology & Pharmaceuticals space.
Based on the USPTO statutory response window for each pending office action. 11 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 11 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (2%) |
| §101 + other | 9 (22%) |
| §103 only | 4 (10%) |
| §102 only | 1 (2%) |
| §112 only | 5 (12%) |
| Double-patenting + other | 5 (12%) |
| Multi-statute (no §101) | 15 (38%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| IVICH, FERNANDO NMN | 2 | 48.7% | +69.8% |
| KELLY, ROBERT M | 1 | 74.1% | +24.6% |
| WEBSTER, KARMEL JOHANNA | 1 | 68.0% | +28.7% |
| SHELTON, SYNPHANE LA'SHAWN | 1 | 100.0% | +0.0% |
| WILLIAMS, KEITH RICHARD | 1 | 50.0% | +0.0% |
| PAHAKIS, MANOLIS Y | 1 | 69.9% | +48.0% |
| BOLDEN, ELIZABETH A | 1 | 85.1% | +22.1% |
| LEE, CLAY C | 1 | 54.7% | +57.5% |
| AKAR, SERKAN | 1 | 66.0% | +33.7% |
| MURESAN, ANA Z | 1 | 75.0% | +31.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18224345 | NON-PROTEIN PHENYLALANINE ANALOGUES FOR INHIBITING CYANOBACTERIA AND PLANT GROWTH | LIU, SUE XU | 168d overdue |
| 17614563 | ARTIFICIAL RECEPTORS, RECOMBINANT CELLS COMPRISING THEREOF, METHODS FOR THEIR PREPARATION, AND METHOD OF USING THEREOF | IVICH, FERNANDO NMN | 168d overdue |
| 18106903 | TREATMENT OF AN ISCHEMIC HEART DISEASE | TAYLOR, LIA ELAN | 121d overdue |
| 18281341 | ACYL ACTIVATING ENZYME AND A TRANSGENIC CELL, TISSUE, AND ORGANISM COMPRISING SAME | SPEED, DEQUANTARIUS JAVON | 117d overdue |
| 18701580 | SYSTEM FOR DETECTING AND/OR ASSESSING A SUBDURAL HEMATOMA | AKAR, SERKAN | 10d overdue |
| 18557941 | Biomarkers for Neurodegenerative Disease | COUNTS, GARY W | 13d |
| 17958516 | METHODS OF DIAGNOSING CANCER AND PREDICTING RESPONSIVENESS TO THERAPY | SWITZER, JULIET CAROLINE | 72d |
| 18942735 | COMMENSAL FUNGUS AND USES THEREOF | KELLY, ROBERT M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17614563 | ARTIFICIAL RECEPTORS, RECOMBINANT CELLS COMPRISING THEREOF, METHODS FOR THEIR PREPARATION, AND METHOD OF USING THEREOF | IVICH, FERNANDO NMN | 168d overdue |
| 17637098 | SCALED-UP METHODS FOR PURIFYING ANTIBODIES | IVICH, FERNANDO NMN | 44d overdue |
| 18701580 | SYSTEM FOR DETECTING AND/OR ASSESSING A SUBDURAL HEMATOMA | AKAR, SERKAN | 10d overdue |
| 18942735 | COMMENSAL FUNGUS AND USES THEREOF | KELLY, ROBERT M | — |
| 18859560 | DIAGNOSING AND TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER | WEBSTER, KARMEL JOHANNA | — |
| 18726614 | PHOTODYNAMIC THERAPY SYSTEM AND METHOD | PAHAKIS, MANOLIS Y | — |
| 18668340 | ELECTROSTRICTIVE MATERIALS BASED ON DOPED CERIA | BOLDEN, ELIZABETH A | — |
| 18704571 | Robust multi-qubit gates for quantum computing | LEE, CLAY C | — |
| Art Unit | Apps |
|---|---|
| 1678 | 3 |
| 1663 | 2 |
| 1641 | 2 |
| 1616 | 2 |
| 1653 | 2 |
| 1645 | 2 |
| 1644 | 2 |
| 3796 | 1 |
| 3797 | 1 |
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18942735 | COMMENSAL FUNGUS AND USES THEREOF | KELLY, ROBERT M | — | §101§112 | Non-Final OA | — | Pending | Nov 10, 2024 |
| 18859560 | DIAGNOSING AND TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER | WEBSTER, KARMEL JOHANNA | — | §101§102§103 | Non-Final OA | — | Pending | Oct 24, 2024 |
| 18855903 | ALCOHOL ACYLTRANSFERASE AND A TRANSGENIC CELL, TISSUE, AND ORGANISM COMPRISING SAME | SHELTON, SYNPHANE LA'SHAWN | — | §101§112DP | Non-Final OA | — | Pending | Oct 10, 2024 |
| 18845798 | TRANSGENIC HELICHRYSUM UMBRACULIGERUM CELL, TISSUE, OR PLANT | WILLIAMS, KEITH RICHARD | 1663 | §103§112 | Non-Final OA | — | Pending | Sep 10, 2024 |
| 18726614 | PHOTODYNAMIC THERAPY SYSTEM AND METHOD | PAHAKIS, MANOLIS Y | 3796 | §102§103 | Non-Final OA | — | Pending | Jul 03, 2024 |
| 18668340 | ELECTROSTRICTIVE MATERIALS BASED ON DOPED CERIA | BOLDEN, ELIZABETH A | — | §102§103§112 | Non-Final OA | — | Pending | May 20, 2024 |
| 18704571 | Robust multi-qubit gates for quantum computing | LEE, CLAY C | — | §103 | Non-Final OA | — | Pending | Apr 25, 2024 |
| 18701580 | SYSTEM FOR DETECTING AND/OR ASSESSING A SUBDURAL HEMATOMA | AKAR, SERKAN | 3797 | §102§103§112 | Non-Final OA | 10d overdue | Pending | Apr 15, 2024 |
| 18692847 | PROCESS FOR THE PREPARATION OF THE SALBUTAMOL INTERMEDIATE | MURESAN, ANA Z | — | §103§112 | Non-Final OA | — | Pending | Mar 18, 2024 |
| 18692039 | MULTISPECIFIC ANTIBODIES FOR USE IN TREATING DISEASES | GUSTILO, ESTELLA M | — | §102§103§112DPOther | Non-Final OA | — | Pending | Mar 14, 2024 |
| 18106903 | TREATMENT OF AN ISCHEMIC HEART DISEASE | TAYLOR, LIA ELAN | 1641 | §103§112Other | Final Rejection | 121d overdue | Pending | Mar 08, 2024 |
| 18688809 | SPIKY METAL STRUCTURES | BRAZIN, JACQUELINE | — | §102§103 | Non-Final OA | — | Pending | Mar 04, 2024 |
| 18292946 | IRON-CATALYZED METATHESIS POLYMERIZATION OF OLEFINS | BROOKS, KREGG T | — | §102§112 | Non-Final OA | — | Pending | Jan 29, 2024 |
| 18421666 | EX-VIVO CULTURE SYSTEM AND METHODS OF USING SAME | ZHANG SPIERING, DONGXIU | 1616 | §103 | Non-Final OA | — | Pending | Jan 24, 2024 |
| 18408385 | T-CELLS COMPRISING ANTI-CD38 AND ANTI-CD138 CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | BUNNER, BRIDGET E | — | §112DP | Non-Final OA | — | Pending | Jan 09, 2024 |
| 18530406 | COMBINED TREATMENT FOR CANCER | KARUNASENA, ENUSHA | 1653 | §101§103§112 | Non-Final OA | — | Pending | Dec 06, 2023 |
| 18522466 | ANTI-MICROBIAL PEPTIDE (AMP) SIGNATURES FOR DIAGNOSTICS, STRATIFICATION, AND TREATMENT OF MICROBIOME-ASSOCIATED DISEASE | SVEIVEN, MICHAEL CAMERON | — | §101§102§103 | Non-Final OA | — | Pending | Nov 29, 2023 |
| 18387165 | METHOD FOR INDUCING HYPERTROPHIC MUSCLE FIBERS FOR INDUSTRIAL MEAT PRODUCTION | TAKENAKA, RISA | 1632 | §102§103§112 | Non-Final OA | — | Pending | Nov 06, 2023 |
| 18557941 | Biomarkers for Neurodegenerative Disease | COUNTS, GARY W | 1678 | §101 | Non-Final OA | 13d | Pending | Oct 29, 2023 |
| 18281341 | ACYL ACTIVATING ENZYME AND A TRANSGENIC CELL, TISSUE, AND ORGANISM COMPRISING SAME | SPEED, DEQUANTARIUS JAVON | 1663 | §101§103§112 | Non-Final OA | 117d overdue | Pending | Sep 11, 2023 |
| 18281536 | PRENYLTRANSFERASE AND A TRANSGENIC CELL, TISSUE, AND ORGANISM COMPRISING SAME | PAK, YONG D | 1652 | §101§112DP | Non-Final OA | — | Pending | Sep 11, 2023 |
| 18234902 | GENETICALLY MODIFIED BACTERIA FOR GENERATING VACCINES | DUFFY, PATRICIA ANN | 1645 | §102§103§112 | Non-Final OA | — | Pending | Aug 17, 2023 |
| 18224345 | NON-PROTEIN PHENYLALANINE ANALOGUES FOR INHIBITING CYANOBACTERIA AND PLANT GROWTH | LIU, SUE XU | 1616 | §103§112 | Final Rejection | 168d overdue | Pending | Jul 20, 2023 |
| 18258812 | METHACRYLAMIDES PROTEIN BINDERS AND USES THEREOF | WILLIS, DOUGLAS M | 1624 | §112 | Non-Final OA | — | Pending | Jun 22, 2023 |
| 18140095 | AGENTS BINDING MODIFIED ANTIGEN PRESENTED PEPTIDES AND USE OF SAME | BEVERIDGE, CONNOR HAMMOND | — | §101§103 | Non-Final OA | — | Pending | Apr 27, 2023 |
| 18107573 | MAGE-A1 SPECIFIC T CELL RECEPTOR AND USES THEREOF | DUNN, LINDSAY MICHELLE | 1644 | §112 | Non-Final OA | — | Pending | Feb 09, 2023 |
| 17999934 | QUANTUM SIMULATION WITH TRAPPED IONS IN A GRADIENT FIELD | SHALABY, AHMAD HUSSAM | 2187 | §103 | Final Rejection | 5d overdue | Pending | Nov 28, 2022 |
| 18048873 | SYSTEM AND METHOD FOR ULTRASOUND ANALYSIS | CELESTINE, NYROBI I | 3798 | §103 | Final Rejection | 2d overdue | Pending | Oct 24, 2022 |
| 17958516 | METHODS OF DIAGNOSING CANCER AND PREDICTING RESPONSIVENESS TO THERAPY | SWITZER, JULIET CAROLINE | 1682 | §101§102§103§112 | Non-Final OA | 72d | Pending | Oct 03, 2022 |
| 17915500 | VARIANTS OF BETA-GLUCOCEREBROSIDASE FOR USE IN TREATING GAUCHER DISEASE | XU, QING | 1656 | §112 | Final Rejection | 15d | Pending | Sep 29, 2022 |
| 17884594 | METHOD FOR ANALYZING CELL CLUSTERS | BUNKER, AMY M | 1684 | §102 | Non-Final OA | — | Pending | Aug 10, 2022 |
| 17870876 | MULTISPECIFIC ANTIBODIES FOR USE IN TREATING DISEASES | LUNDE, GRACE HENRY | 1641 | §103§112DP | Final Rejection | — | Pending | Jul 22, 2022 |
| 17794268 | ARTICLES OF MANUFACTURE COMPRISING ANTI PD-L1 ANTIBODIES AND THEIR USE IN THERAPY | DRISCOLL, MAUREEN VARINA | 1644 | §103§112 | Non-Final OA | — | Pending | Jul 21, 2022 |
| 17839667 | MICROFLUIDIC DEVICE FOR ANALYZING GENE EXPRESSION | MARVICH, MARIA | 1634 | §112 | Final Rejection | — | Pending | Jun 14, 2022 |
| 17779704 | CHIMERIC ANTIGEN RECEPTOR TO CARBOHYDRATE ANTIGENS | DONOGHUE, BRITTNEY ERIN | 1675 | §112DP | Final Rejection | — | Pending | May 25, 2022 |
| 17637098 | SCALED-UP METHODS FOR PURIFYING ANTIBODIES | IVICH, FERNANDO NMN | 1678 | §102§103§112DP | Non-Final OA | 44d overdue | Pending | Feb 22, 2022 |
| 17614563 | ARTIFICIAL RECEPTORS, RECOMBINANT CELLS COMPRISING THEREOF, METHODS FOR THEIR PREPARATION, AND METHOD OF USING THEREOF | IVICH, FERNANDO NMN | 1678 | §103§112Other | Final Rejection | 168d overdue | Pending | Nov 29, 2021 |
| 17515591 | COMPOSITIONS COMPRISING THE PROPEPTIDE OF LYSYL OXIDASE AND USES THEREOF | ALFANO, ALAN | 1600 | §103§112 | Final Rejection | — | Pending | Nov 01, 2021 |
| 16885331 | CONDITIONING PROTOCOLS AND USE OF SAME FOR TISSUE REGENERATION | MARTIN, PAUL C | 1653 | §103§112 | Final Rejection | — | Pending | May 28, 2020 |
| 16331863 | THERMOSTABLE VARIANTS OF P. FALCIPARUM PFRH5 WHICH CAN BE PRODUCED IN BACTERIAL CELLS | ZEMAN, ROBERT A | 1645 | §112 | Final Rejection | — | Pending | Mar 08, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial